Vitamin Shoppe downgraded to Underperform from Neutral at BofA/Merrill BofA/Merrill downgraded Vitamin Shoppe citing the deceleration in comps and increased competition following the Q1 report. Price target lowered to $40 from $55.
Vitamin Shoppe positioned for outperformance, says Susquehanna Susquehanna believes Vitamin Shoppe is well positioned for outperformance ahead of Q1 results. The firm believes Q4 results were not indicative of the company's growth prospects given expectations for a combination of same store sales strength, margin expansion, and unit growth. Shares are Positive rated with a $67 price target.